Active	Status	Sponsor type	Region	Phase	Filter
5 Active 1 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Sharma, Vivek R
A021806, NCT04340141: Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer	Recruiting	3	352	Canada, US	Oxaliplatin, Irinotecan Hydrochloride, Leucovorin Calcium, Fluorouracil, Resection, Questionnaire Administration	Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)	Pancreatic Adenosquamous Carcinoma, Resectable Pancreatic Adenocarcinoma, Pancreatic Cancer	01/26	11/30
VIRAGE, NCT05673811: Study of Nab-Paclitaxel and Gemcitabine and Plus/minus VCN-01 in Patients with Metastatic Pancreatic Cancer	Active, not recruiting	2	96	Europe, US	Nab-paclitaxel, Gemcitabine, VCN-01	Theriva Biologics SL	Pancreatic Adenocarcinoma, Metastatic	04/25	04/25
BCC-RAD-13, NCT02128100: Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer	Completed	2	5	US	Folfirinox, o Oxaliplatin, o Leucovorin, o Irinotecan, o Fluorouracil, Stereotactic Body Radiation Therapy	University of Louisville, James Graham Brown Cancer Center	Pancreatic Cancer Non-resectable	03/21	03/21
ASIST, NCT05322590: BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma	Active, not recruiting	1/2	195	US	BXQ-350, SapC-DOPS, Placebo	Bexion Pharmaceuticals, Inc., ICON plc, CTI Clinical Trial and Consulting Services	Metastatic Colorectal Carcinoma, Neuropathy	04/26	04/29
NCT03994627: Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma	Approved for marketing	N/A		Europe, Canada, US, RoW	Olaratumab, LY3012207	Eli Lilly and Company	Soft Tissue Sarcoma